More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones. But in 2004 Gilead executives stopped the research, only to restart it as the expiration of tenofovir’s patent in 2018 neared.
19 hours ago | Los Angeles Times
Accumulating evidence suggests that rates of low bone mass are greater in HIV-infected males than in females. Researchers led by Grace Aldrovandi, MD, chief of the Division of Infectious Diseases at Children's Hospital Los Angeles, studied 11 biomarkers associated with inflammation, bone loss and/or bone formation in about 450 individuals -- assessed by sex and HIV status -- to try to determine causes of this differential bone loss.
11 March 2016 | Eurekalert Medicine & Health
The free website, entitled "How Rehabilitation Can Help People Living with HIV in Sub-Saharan Africa: An Evidence-Informed Tool for Rehab Providers", was adapted from a Canadian resource and is also downloadable for use on paper. It's designed to be a one-stop resource for physiotherapists, occupational therapists and other health workers who can quickly and easily research the most common HIV-related disabilities, and find evidence-based rehabilitation solutions
02 December 2015 | Eurekalert Medicine & Health
Including tenofovir alafenamide (TAF) in single-tablet elvitegravir/cobicistat/emtricitabine (E/C/F/TAF) is associated with reduced renal and bone toxicity compared to tenofovir disoproxil fumarate (TDF)-containing single-tablet (E/C/F/TDF) therapy, according to an analysis of data from two Phase 3 trials, reported at IDWeek 2015.
12 October 2015 | Monthly Prescribing Reference
HIV infection inflated the risk of a new fracture 32% in a mostly premenopausal group in the Women's Interagency HIV Study (WIHS). Older age, white race, previous fracture history, injection drug use, opiate use and smoking also independently raised the risk of any fracture in multivariate analysis.
05 October 2015 | The Body
A fixed-dose combination pill containing tenofovir alafenamide (TAF) worked as well in a Phase 3 trial as the current Truvada pill containing the older tenofovir disoproxil fumarate (TDF) -- which is used for both HIV treatment and pre-exposure prophylaxis or PrEP -- but causes less kidney and bone toxicity, according to an announcement this week from Gilead Sciences.
04 September 2015 | HIVandHepatitis.com
Patients with HIV infection who take antiretroviral therapy (ART) can also reduce antiretroviral therapy-related bone loss by 50% by taking daily high-dose vitamin D and calcium supplements, according to a 48-week study.
17 June 2015 | Medscape
In Amsterdam, researchers have established a large cohort, called AGEhIV, of both HIV-positive and HIV-negative people of similar age and risk behaviours. Young MSM in this study, regardless of HIV infection, were surprisingly at risk for having thinner-than-normal bones.
01 October 2014 | CATIE
Gilead is running nine phase III studies involving tenofovir alafenamide (TAF), which reflects the importance of the drug to Gilead's future HIV business. It is collecting an enormous amount of clinical data in which to make the case that TAF should be a preferred backbone drug for new and existing HIV patients, as well as patients who cannot use Viread because of pre-existing kidney conditions.
23 September 2014 | The Street
People living with HIV are at greater risk of geriatric syndromes such as frailty and difficulty with daily activities than HIV negative people of the same age -- and this can have a significant effect upon their quality of life as they age, according to several studies presented at the 14th Conference on Retroviruses and Opportunistic Infections (CROI 2014) last month in Boston.
08 April 2014 | HIVandHepatitis.com